AI Article Synopsis
- Stereotactic ablative body radiotherapy (SABR) delivers precise high doses of radiation to specific tumors using advanced imaging and immobilization techniques.
- SABR is becoming a key treatment for primary kidney cancer, particularly when surgery isn't an option, and is increasingly used for low-volume stage IV kidney cancers to postpone or extend systemic therapy.
- The review will assess the effectiveness and challenges of using SABR for treating oligometastatic renal cell carcinoma.
Article Abstract
Stereotactic ablative body radiotherapy (SABR) aims to accurately deliver a higher than conventional dose of radiotherapy to a well-defined target tumour incorporating advanced immobilisation and imaging techniques. SABR is an emerging treatment option for primary kidney cancer especially when surgery is contraindicated. Increasingly, SABR is being incorporated into the management of low-volume stage IV kidney cancers to delay the need for systemic therapy or to prolong the duration of ongoing systemic treatment. This review will evaluate the evidence and limitations of SABR for oligometastatic renal cell carcinoma.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10877104 | PMC |
| http://dx.doi.org/10.1016/j.ctro.2024.100739 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!